Apogee Therapeutics
APGE
206 hedge funds and large institutions have $5.27B invested in Apogee Therapeutics in 2025 Q4 according to their latest regulatory filings, with 53 funds opening new positions, 85 increasing their positions, 46 reducing their positions, and 19 closing their positions.
179% more first-time investments, than exits
New positions opened: 53 | Existing positions closed: 19
125% more funds holding in top 10
Funds holding in top 10: 4 → 9 (+5)
122% more capital invested
Capital invested by funds: $2.37B → $5.27B (+$2.9B)
93% more call options, than puts
Call options by funds: $27.8M | Put options by funds: $14.4M
85% more repeat investments, than reductions
Existing positions increased: 85 | Existing positions reduced: 46
18% more funds holding
Funds holding: 174 → 206 (+32)
27.12% less ownership
Funds ownership: 129.22% → 102.11% (-27%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$172M |
| 2 |
Janus Henderson Group
London,
|
+$99.3M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$82.4M |
| 4 |
BlackRock
New York
|
+$69.2M |
| 5 |
PA
Perceptive Advisors
New York
|
+$61.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
B
Braidwell
Stamford,
Connecticut
|
-$54.4M |
| 2 |
Barclays
London,
United Kingdom
|
-$32.1M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$25.3M |
| 4 |
PBA
Paradigm Biocapital Advisors
New York
|
-$25.1M |
| 5 |
JFG
Jefferies Financial Group
New York
|
-$22.6M |
APGE Hedge Fund Activity: Q4 2025 in Review
206 of the 8,265 institutional investors tracked by Wall St. Rank reported a position in Apogee Therapeutics (APGE) for Q4 2025, worth a combined $5.27B — up 122% from $2.37B a quarter earlier.
Buyers outnumbered sellers: 53 funds opened new APGE positions and 19 closed out — a net gain of 34 holders — while 85 added to existing stakes and 46 trimmed.
The largest buyer was T. Rowe Price Investment Management, adding an estimated $172M. The largest seller was Braidwell, cutting an estimated $54.4M.
- 206 institutional investors held Apogee Therapeutics (APGE) as of Q4 2025, up from 174 in Q3 2025.
- Funds reported $5.27B of Apogee Therapeutics stock for Q4 2025, up 122% quarter-over-quarter.
- 53 funds opened new Apogee Therapeutics positions in Q4 2025 and 19 closed out, a net change of +34 holders.
- The largest Apogee Therapeutics buyer in Q4 2025 was T. Rowe Price Investment Management, an estimated $172M added.
- The largest Apogee Therapeutics seller in Q4 2025 was Braidwell, an estimated $54.4M sold.
Based on aggregated 13F filings for Q4 2025.